Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UnchAIN secukinumab study in rotator cuff tendinopathy
2022-001516-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in shoulder tendinopathy comparing Secukinumab plus individualized conventional therapy with Placebo plus individualized conventional therapy (2 arms). Primary endpoint: Mean change in Western Ontario Rotator Cuff index score from baseline to week 24. Started Aug 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
shoulder tendinopathy
Beyond the preview
Go deeper on 2022-001516-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001516-26.